Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -103.63% is 45% above its 5-year average of -188.72%, near the high end of its 5-year range (-458.23%–-22.59%).
45.64% below its 12-month average of -71.15%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -48.27%.
EBITDA MARGIN
-103.63%
EBITDA MARGIN AVG TTM
-71.15%
EBITDA MARGIN AVG 3Y
-128.08%
EBITDA MARGIN AVG 5Y
-188.72%
EBITDA MARGIN AVG 10Y
-177.30%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-45.64%
CURRENT VS 3Y AVG
+19.09%
CURRENT VS 5Y AVG
+45.09%
CURRENT VS 10Y AVG
+41.55%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Fortress Biotech, Inc.
Market Cap
$141.70M
EBITDA Margin
-103.63%
TTM Avg
-71.15%
3Y Avg
-128.08%
5Y Avg
-188.72%
Market Cap
$141.09M
EBITDA Margin
5.24%
TTM Avg
5.41%
3Y Avg
5.74%
5Y Avg
10.79%
Market Cap
$139.63M
EBITDA Margin
-221.15%
TTM Avg
-221.15%
3Y Avg
-221.15%
5Y Avg
-221.15%
Market Cap
$145.39M
EBITDA Margin
-16238.30%
TTM Avg
-8929.91%
3Y Avg
-4730.54%
5Y Avg
-4730.54%
Market Cap
$137.57M
EBITDA Margin
-5.26%
TTM Avg
-11.06%
3Y Avg
-22.91%
5Y Avg
-20.50%
Market Cap
$146.95M
EBITDA Margin
-239.78%
TTM Avg
-210.59%
3Y Avg
-2213.91%
5Y Avg
-2345.87%
Market Cap
$148.07M
EBITDA Margin
-550.97%
TTM Avg
-275.49%
3Y Avg
-275.49%
5Y Avg
-275.49%
Market Cap
$135.17M
EBITDA Margin
-0.19%
TTM Avg
-1.66%
3Y Avg
-11.02%
5Y Avg
-42.72%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. (FBIOP) | $141.70M | -103.63% | -71.15% | -128.08% | -188.72% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $141.09M | 5.24% | 5.41% | 5.74% | 10.79% |
| Alpha Cognition Inc (ACOG)vs › | $139.63M | -221.15% | -221.15% | -221.15% | -221.15% |
| Freenome, Inc. (FRNM)vs › | $138.31M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $145.39M | -16238.30% | -8929.91% | -4730.54% | -4730.54% |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.57M | -5.26% | -11.06% | -22.91% | -20.50% |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.95M | -239.78% | -210.59% | -2213.91% | -2345.87% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $148.07M | -550.97% | -275.49% | -275.49% | -275.49% |
| LifeMD, Inc. (LFMD)vs › | $135.17M | -0.19% | -1.66% | -11.02% | -42.72% |
| Health Catalyst, Inc. (HCAT)vs › | $131.16M | 4.63% | -2.31% | -16.32% | -24.77% |
Gross Margin
62.5%
EBITDA Margin
-103.6%
Operating Margin
-111.0%
Net Margin
163.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -48.27% |
| 2026-03-31 | -37.66% |
| 2025-12-31 | -22.59% |
| 2025-09-30 | -32.07% |
| 2025-06-30 | -215.18% |
| 2025-03-31 | -160.79% |
| 2024-12-31 | -170.24% |
| 2024-09-30 | -128.32% |
| 2024-06-30 | -178.55% |
| 2024-03-31 | -271.49% |
| 2023-12-31 | -89.77% |
| 2023-09-30 | -31.67% |
| 2023-06-30 | -278.41% |
| 2023-03-31 | -458.23% |
| 2022-12-31 | -317.25% |
| 2022-09-30 | -287.40% |
| 2022-06-30 | -257.88% |
| 2022-03-31 | -188.40% |
| 2021-12-31 | -330.05% |
| 2021-09-30 | -228.54% |
| 2021-06-30 | -230.26% |
| 2021-03-31 | -245.23% |
| 2020-12-31 | -166.80% |
| 2020-09-30 | -229.08% |
| 2020-06-30 | -254.46% |
| 2020-03-31 | -156.70% |
| 2019-12-31 | -261.55% |
| 2019-09-30 | -218.08% |
| 2019-06-30 | -261.96% |
| 2019-03-31 | -486.52% |
| 2018-09-30 | -42.04% |
| 2018-06-30 | -37.76% |
| 2018-03-31 | -59.51% |
| 2017-12-31 | -59.45% |
| 2017-09-30 | -67.78% |
| 2017-06-30 | -44.14% |
| 2017-03-31 | -37.51% |
| 2016-12-31 | -145.86% |
| 2016-09-30 | -1646.26% |
| 2016-06-30 | -674.66% |
| 2016-03-31 | -2285.91% |
| 2015-12-31 | -3732.84% |
| 2015-09-30 | -72264.00% |
| 2015-03-31 | -2413.00% |
